Plain-spoken notes on the compounds we supply — what the literature shows, how to read a COA, and the protocols that protect your data. Cited, never hyped.
In the news
The GLP-1 shortage spawned a compounding boom. As the FDA winds it down, semaglutide is left as three distinct things that share a molecule's…
In the news
Blueprint's founder has run dozens of peptides through his body and his biomarkers. Ranked by evidence, his protocol separates the plausible from the speculative…
In the news
Retatrutide is a real phase III triple agonist that produced some of the largest weight-loss figures in trial history. The vial sold on a…
In the news
In a few short years, peptides went from obscure lab reagents to the most-discussed molecules in longevity and biohacking culture. A look at why…
In the news
On 20 April 2026, one of the world's biggest podcasts told millions that Big Pharma is hiding a powerful peptide. We checked the science,…
In the news
On 1 June 2026, Huberman Lab spent a full episode on peptides. It was more careful than most of the internet. Here is what…
Occasional, considered notes on the compounds and the literature. No noise.
Subscribe & earn 500 pointsCookies
We use strictly necessary cookies to run the store. With your consent we also use analytics (order attribution) and marketing (Omnisend) cookies. Read our Cookie Policy.
